复发或难治性外周T细胞淋巴瘤-非特指型与血管免疫母细胞性T细胞淋巴瘤患者的生存结局
分析1999至2015年新诊断的321例外周T细胞淋巴瘤-非特指型(PTCL-NOS,n=180)或血管免疫母细胞性T细胞淋巴瘤(AITL,n=141)患者,240例(PTCL-NOS 135例、AITL 105例)出现进展或复发。中位随访52个月,PTCL-NOS患者中位FFS1、FFS2、FFS3分别为3.1、2.5、2.1个月,AITL患者分别为5.5、2.9、2.3个月;1999至2015年间FFS1和OS1未见改善。普拉曲沙和罗米地辛后中位FFS分别仅3.0和2.5个月;挽救性自体移植和异基因移植后5年OS率分别为32%和52%,未移植患者为10%。
要点
- PTCL-NOS患者中位FFS1、FFS2、FFS3分别为3.1、2.5、2.1个月,AITL患者分别为5.5、2.9、2.3个月。
- 1999至2015年间复发时FFS1和OS1未见改善。
- 普拉曲沙和罗米地辛后中位FFS分别仅3.0和2.5个月。
核心结论
- PTCL-NOS和AITL患者疾病进展或复发后生存结局仍很差,需要进一步研究疗效更高且安全性更好的新治疗方法。
研究设计与样本
- 分析1999年至2015年间新诊断的321例PTCL-NOS(n=180)或AITL(n=141)患者,从首次、第二次和第三次疾病进展时分别计算FFS1/OS1、FFS2/OS2和FFS3/OS3。
主要发现
- 中位随访52个月,240例患者(PTCL-NOS 135例、AITL 105例)出现进展或复发。
- PTCL-NOS患者中位FFS1、FFS2和FFS3分别为3.1、2.5和2.1个月;AITL患者分别为5.5、2.9和2.3个月。
- 1999至2004年、2005至2009年和2010至2015年期间,复发时FFS1和OS1未见改善。
- 普拉曲沙和罗米地辛后中位FFS分别仅3.0和2.5个月。
- 挽救性自体移植和异基因移植后5年OS率分别为32%和52%,未接受移植患者为10%。
局限性
- 原文结论指出需要进一步研究疗效更高且安全性更好的新治疗方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease progression/relapse remains very poor. A total of 321 patients, newly diagnosed with PTCL-NOS (n = 180) or AITL (n = 141) between 1999 and 2015, were analysed. Failure-free survival (FFS) and overall survival (OS) were calculated from the time of first disease progression (FFS1, OS1), from second disease progression (FFS2, OS2) and from third progression (FFS3, OS3). With a median follow-up duration of 52 months, 240 patients (135 PTCL-NOS, 105 AITL) experienced progression/relapse. In patients with PTCL-NOS, the median durations of FFS1, FFS2 and FFS3 were 3·1, 2·5 and 2·1 months, respectively. In patients with AITL, they were 5·5, 2·9 and 2·3 months, respectively. There was no improvement in FFS1 and OS1 by the time of recurrence during this period (1999-2004, 2005-2009 and 2010-2015). The median FFS after pralatrexate and romidepsin was only 3·0 and 2·5 months, respectively. The 5-year OS rates after salvage autologous and allogeneic transplant were 32% and 52%, respectively; while the 5-year OS rates for patients who did not undergo transplant was 10%. Further research for novel therapeutic approaches with higher efficacy and better safety profile are needed.
引用
- Chihara D, Fanale MA, Miranda RN, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2016. PMID: 27983760. doi:10.1111/bjh.14477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。